CTCFL and breast carcinoma: While initiating a study to investigate the molecular mechanism(s) leading to the aberrant BORIS expression in breast cancers, we have obtained similar discordant results regarding the expression of BORIS. Using sensitive RT-PCR-based assays, employing multiple primer sets, we find that neither mature BORIS transcripts, nor spliced variants, are commonly expressed in malignant breast cells.